University of Hertfordshire

From the same journal

By the same authors


  • Nazish Khan
  • Mamas A. Mamas
  • Alexandra Moss
  • Diana A. Gorog
  • Peter Nightingale
  • Angel Armesilla
  • Andrew Smallwood
  • Shahzad Munir
  • Saib Khogali
  • Ben Wrigley
  • James M. Cotton
View graph of relations
Original languageEnglish
Pages (from-to)523-525
Number of pages3
JournalThrombosis Research
Publication statusPublished - 10 Sep 2020


Aspirin, the most commonly prescribed antiplatelet agent in clinical practice, forms a cornerstone of management in patients with established cardiovascular disease (CVD). The clinical efficacy and safety of aspirin when prescribed for secondary prevention is supported by a robust evidence base demonstrating a 24% reduction in mortality and a 25% reduction in serious adverse events without any increase in bleeding complications in the context of an acute myocardial infarction [ 1 ]. Nevertheless, numerous studies have shown that the antiplatelet effect of aspirin is not uniform and is often sub-optimal in a sizable proportion of patients [ 2 , 3 ]. Inadequate platelet inhibition following the administration of aspirin is associated with recurrent cardiovascular events and adverse outcomes in patients with coronary artery disease [ 2 ].

ID: 22962995